Professor of Medicine, UCSF
Oncology
Dr. Andrew H. Ko, MD
|
|
Give Review
Andrew works in the field of Oncology. He researched medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He over the years received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Doctor Andrew H. Ko, MD is a published doctor and has 62 publications published. The lastest was: 'Effects of cardiotrophin-1 on haemodynamics and cardiac function in conscious rats.'
Publications
- A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
- MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic Cancer.
- Metformin use among type 2 diabetics and risk of pancreatic Cancer in a clinic-based case-control study.
- Statin use and risk of pancreatic Cancer: Results from a large, clinic-based case-control study.
- A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract Cancer.
- Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
- Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled Analysis of 7 prospective trials of ge...
- Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?: A Pooled Analysis of Phase II Trials of Gemcitabine-Containing...
- Beyond first-line chemotherapy for advanced pancreatic Cancer: An expanding array of therapeutic options?
- Evolving treatment options for locally advanced unresectable pancreatic Ductal adenocarcinoma.
- (90)Y Glass Microspheres for the Treatment of Unresectable Metastatic Liver Disease from Chemotherapy-Refractory Gastrointestinal Cancers: A Pilot Study.
- A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced coloRectal cancer.
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic Cancer.
- Subtype Specific MEK - PI3 Kinase Feedback as a Therapeutic Target in Pancreatic AdenoCarcinoma.
- Temsirolimus combined with sorafenib in hepatocellular Carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
- Achieving the Best of Both Worlds.
- A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic Cancer.
- Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- FOLFIRINOX: A Small Step or a Great Leap Forward?
- A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenoCarcinoma.
- Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced ...
- "And what other medications are you taking?".
- Subtypes of pancreatic Ductal adenocarcinoma and their differing responses to therapy.
- Radiation therapy in operable and locally advanced pancreatic Cancer.
- A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
- Personalized medicine for pancreatic Cancer: a step in the right direction.
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic Cancer: is an anti-VEGF strate...
- Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic Cancer receiving chemotherapy.
- Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic Cancer: results of a phase II study.
- Future strategies for targeted therapies and tailored patient management in pancreatic Cancer.
- A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic Cancer.
- Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenoCarcinoma of the pancreas.
- Systemic therapy for pancreatic Cancer.
- Treatment of metastatic pancreatic Cancer.
- Tumor-associated hypoglycemia from metastatic coloRectal adenocarcinoma: case report and review of the literature.
- Current and future strategies for combined-modality therapy in pancreatic Cancer.
- Erlotinib in the treatment of advanced pancreatic Cancer.
- A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic Cancer.
- Characterization of circulating tumor Cell aggregates identified in patients with epithelial tumors.
- Fluid biopsy in patients with metastatic prostate, pancreatic and breast Cancers.
- Pancreatic Cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California.
- Clinical outcomes associated with very late relapses in diffuse large cell Lymphoma.
- Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic Cancer.
- Vaccination of metastatic coloRectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
- Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
- Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T Cell-mediated insulin-dependent diabetes mellitus.
- Self-tolerance and the composition of T Cell repertoire.
- CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen.
- Radiation after mastectomy in high-risk patients: is it necessary?
- Treatment of pseudoTumors with nonsteroidal antiinflammatory drugs.
- AR and ER interaction with a p21-activated kinase (PAK6).
- A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.
- Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition.
- Effects of vascular endothelial growth factor on hemodynamics and cardiac performance.
- Novel Analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats.
- Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo.
- In vivo effects of cardiotrophin-1.
- Hemodynamic effects of scatter factor in conscious rats.
- Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection.
- Effects of cardiotrophin-1 on haemodynamics and cardiac function in conscious rats.
- Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary Lung lesions in a patient with AIDS: an HIV-associated collision tumor.
Schools
Johns Hopkins University School Of Medicine
Beth Israel Hospital
Stanford University Med Center
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
Stanford University -
Johns Hopkins University School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1851355853 | |
| NPPES Provider LastName | KO | |
| NPPES Provider FirstName | ANDREW | |
| NPPES Provider ZIPCode | 941430001 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 297.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 59.0 | |
| Percent Opioid Claims | 19.87 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851355853 |
| Last Name Of The Provider | KO |
| First Name Of The Provider | ANDREW |
| View All |
Similar Doctors
|
|
Dr. May C. Chen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bertrand Y. Tuan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David H. Irwin, MD |
|
|
Dr. Mark M. Moasser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Park, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Weiyun Z. Ai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert A. Bok, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sumit A. Shah, MD
This Doctor is OpenDoctor Recommended.
|